Purpose: Carotid artery stenting (CAS) is an established treatment for symptomatic carotid artery stenosis as an alternative to carotid endarterectomy. A variety of techniques and devices have been devised to minimise periprocedural stroke risk using either proximal or distal embolic protection. This study presents a method of embolic protection during CAS—the CaRotid Artery Filtering Technique (CRAFT).

Materials and Methods: The CRAFT technique employs aspects of both proximal and distal embolic protection. The CASPER RX stent (MicroVention, Tustin, CA, USA), which is a double-layered, closed-cell, micromesh nitinol stent, is deployed across the carotid artery stenosis with the assistance of a FlowGate balloon guide catheter (Stryker Neurovascular, Fremont, CA, USA). The partially deployed stent acts as a distal filter while the balloon guide is deflated midway during stent deployment to prevent distal plaque embolisation, followed by completion of stent deployment and angioplasty.

Results: A total of 94 patients underwent CAS using the CRAFT technique between June 2016 and March 2021. Successful stent deployment was achieved in all patients. Preliminary results demonstrated acute stent occlusion in 6 patients (6.4%) and distal embolic stroke in 5 patients (5.3%). The median procedural fluoroscopy time was 34 minutes with an interquartile range of 22 to 55 minutes.

Conclusion: The CRAFT technique of CAS presented by this study can be applied in the treatment of symptomatic carotid artery stenosis in both emergency and elective procedure settings with a high technical success and low distal embolic stroke risk.

Keywords: Carotid arteries; Stents; Radiology; Interventional
INTRODUCTION

Carotid artery stenting (CAS) has an established role in the management of symptomatic carotid artery stenosis. Advancements in imaging, endovascular devices, and techniques have enabled improved technical and clinical outcomes. Whilst CAS offers many benefits over carotid endarterectomy (CEA), such as avoidance of general anaesthesia, injury to adjacent neurovascular structures, reduced risk of wound infection, and reduced length-of-stay, concerns still exist regarding the risk of periprocedural stroke—the most common major complication of CAS. However, large scale clinical trials have demonstrated that the long-term functional outcome, risk of disabling stroke, myocardial infarction or death did not differ significantly between CAS and CEA. In addition, numerous devices and technical methods, including new stents and embolic protection devices, have been designed and trialled, aiming to further reduce the risk of cerebral embolisation during CAS. However, there is still a lack of clear consensus on which combination of strategies is most efficacious.

As a result, substantial heterogeneity exists in the current practice of CAS across different centres and operators, and innovation is needed to establish an ideal technique. The present study describes the technique, efficacy and safety of a method of CAS utilising aspects of both distal and proximal embolic protection, entitled “CaRotid Artery Filtering Technique” (CRAFT).

MATERIALS AND METHODS

This is a retrospective study performed in two comprehensive stroke centres in Australia to evaluate the technical success and peri-procedure complication of CAS using CRAFT. All patients who underwent CAS for symptomatic carotid artery stenosis or occlusion using the CASPER RX stent with CRAFT technique between June 2016 and March 2021 were included in the study. All emergency patients received clinical assessment, computed tomography (CT) angiogram and perfusion studies which confirmed their eligibility for carotid stenting and/or endovascular clot retrieval. All CAS procedures were performed in biplane angiography suites by experienced interventional neuroradiologists. Procedural success and peri-procedural complications were collected from electronic clinical records. This study was approved by the institutional human research ethics committee.

Device Description

The CASPER RX stent (Roadsaver in Europe), “Carotid Artery Stent designed to Prevent Embolic Release” (MicroVention, Tustin, CA, USA), is a nitinol, self-expanding, double-layered micromesh stent with flared ends. The stent has a closed-cell design with tiny cells (375–700 µm) and is available in various

---

Fig. 1. Diagrammatic stepwise breakdown of deploying CASPER RX stent (MicroVention, Tustin, CA, USA) with the assistance of balloon across carotid artery stenosis (CaRotid Artery Filtering Technique, CRAFT). (A) FlowGate Balloon Guide Catheter (BGC) (Stryker Neurovascular, Kalamazoo, MI, USA) and its supplied inner catheter are advanced to the internal carotid artery (ICA), just proximal to the lesion and lesion crossed by guidewire. (B) BGC inflated in ICA causing an arrest of antegrade flow. (C) A CASPER RX stent introduced over the guidewire into the ICA, distal to the lesion and partially deployed. (D) BGC is deflated to restore antegrade flow. (E) Stent is completely deployed into the ICA and CCA. Red arrow indicates direction of blood flow.
sizes, with outer diameters ranging from 5–10 mm and double-layer length ranging from 18–40 mm. The struts have a braided design, allowing conformation to the tortuosity within the internal carotid artery (ICA) and common carotid artery (CCA). The delivery system comprises a 5-French 143 cm length rapid exchange delivery catheter over a 0.014 inch guidewire platform.

**CRAFT Technique**

An 8-French introducer sheath is inserted into the right common femoral artery.

In cases of isolated ICA occlusion, an 8-French FlowGate Balloon Guide Catheter (BGC) (Stryker Neurovascular, Kalamazoo, MI, USA) and its supplied inner catheter are advanced to the CCA or ICA, just proximal to the lesion. An 0.014 inch×200 or 300 cm length microwire (Synchro²; Stryker Neurovascular) (Fig. 1A) is then used to cross the ICA lesion. The BGC is inflated in the CCA or ICA, causing an arrest of antegrade flow (Fig. 1B). A CASPER RX stent (MicroVention) is introduced over the guidewire into the ICA, distal to the lesion. Prior to loading on to the guidewire, the CASPER stent is flushed with anti-IIb/IIIa inhibitor, with the intention to reduce the risk of stent occlusion. The CASPER RX stent is then partially deployed (distal third) such that the double-layered segment of the stent is well apposed to the distal vessel wall (Fig. 1C). At this point, the BGC is deflated to restore antegrade flow, and the partially deployed distal stent acts as an embolic filter due to the micromesh nature of the stent (Fig. 1D). Finally, the stent is completely deployed into the CCA, and angioplasty performed with a 5 or 5.5 mm non-compliant monorail coronary angioplasty balloon (Sterling; Boston Scientific, Marlborough, MA, USA) (Fig. 1E).

In cases of a tandem occlusion, an 8-French FlowGate BGC is inserted over a 0.035 inch guidewire (GlideWire; Terumo, Tokyo, Japan) into the CCA, where angiography is performed to confirm the ICA occlusion. The FlowGate balloon is inflated as the ICA occlusion is crossed using a coaxial system, comprising a 5-French intermediate catheter (SOFIA; MicroVention); a 0.014 inch microwire (Synchro³) and either a Trevo Pro 18 (Stryker Neurovascular) or Headway 21 microcatheter (MicroVention). The microcatheter is navigated past the intracranial occlusion over the microwire, and stent retriever thrombectomy is performed with either a Solitaire (Medtronic, Irvine, CA, USA) or Trevo (Stryker Neurovascular) device of appropriate size. Vacuum syringe suction is applied to the intermediate catheter, through which the stent retriever device is removed. After satisfactory revascularisation, a 0.014 inch×200 or 300 cm length microwire is introduced via the intermediate catheter, in preparation for CAS. The intermediate catheter is then removed before introducing the CASPER RX stent over the microwire into the cervical ICA, beyond the occlusion. As previously described, the FlowGate balloon guide, still proximal to the occlusion, is inflated before partial stent deployment and the distal third of the stent is used as a filter upon deflating the balloon. Complete stent deployment and angioplasty ensue.

If difficulty is encountered upon navigating the microcatheter to the intracranial occlusion, the BGC may be advanced intracranially, through the ICA occlusion, to offer greater distal stability. After stent retriever thrombectomy, the BGC may then be withdrawn to the cervical ICA, just distal to the occlusion, where it is inflated for partial stent deployment, then deflated for stent filtration and full stent deployment.

**Antiplatelet Therapy**

Our experience led us to apply following antiplatelet therapy for patients who received CASPER RX stent with CRAFT technique. In addition, all patients included in this study received antiplatelet therapy as below regardless of whether they received intravenous tissue plasminogen activator or not.

For elective cases, depending on the acuity of presentation, all patients received 500 mg intravenous aspirin followed by 2,000–3,000 units of intravenous heparin when the balloon was inflated. Depending on the time of symptoms onset and the amount of initial ischemic core demonstrated on CT perfusion, repeat CT brain study was performed 2–4 hours after the procedure to confirm the size of ischaemic core and to assess for intracranial haemorrhage. Based the result, the patient received an additional single dose of either 600 or 300 mg clopidogrel.

For emergency cases with acute presentations, all patients received 500 mg intravenous aspirin followed by 2,000–3,000 units of intravenous heparin when the balloon was inflated. Depending on the time of symptoms onset and the amount of initial ischemic core demonstrated on CT perfusion, repeat CT brain study was performed 2–4 hours after the procedure to confirm the size of ischaemic core and to assess for intracranial haemorrhage. Based the result, the patient received an additional single dose of either 600 or 300 mg clopidogrel.

For elective cases, depending on the acuity of presentation, all patients received a loading dose of 600 mg aspirin and 600 mg clopidogrel 3–5 days prior to the procedure followed by a daily dose of 100 mg aspirin and 75 mg of clopidogrel including the day of procedure. During the procedure, prior to stent deployment, 500 mg intravenous aspirin was administered if there was any concern regarding a patient’s platelet aggregation. In addition, 2,000 units of intravenous heparin was administered when the balloon was inflated.

Following carotid artery stenting, when possible, all patients were commenced on dual antiplatelet therapy con-
sisting of 75 mg clopidogrel daily and 100 mg aspirin daily for 6–12 months followed by daily aspirin for several years depend on the clinical status.

RESULTS

A total of 89 patients underwent 94 cases of CAS using the CRAFT technique between June 2016 and March 2021. Patient demographics, basic lesion characteristics and mechanical thrombectomy data are summarized in Tables 1 and 2. The effectiveness and technical feasibility of this technique have been described in our previous publication.4 In the setting of acute stroke, it was shown that this technique had a high technical success rate (100%) and a relatively low complication rate.

Successful stent deployment was achieved in all cases. Preliminary results demonstrated acute stent occlusion in 6 cases (6.4%), and 1 case had recurrent stent occlusion and subsequently died due to extensive middle cerebral artery territory infarct. Five cases (5.3%) had intra-operative or early peri-operative distal embolic stroke in the middle cerebral artery (MCA) territory, and one of these patients had an ICA tear during the procedure in the setting of angioplasty which led to distal occlusion. All five patients who developed distal embolic stroke had clinical symptoms, and occlusions were confirmed on CT angiogram or digital subtraction angiogram. Patients who had distal occlusions underwent successful clot retrieval during the same procedure. Six cases (6.4%) developed intracranial haemorrhage after the procedure and five of them had symptoms related to the haemorrhage. All of these cases were performed in an emergency setting and three patients were previously on anti-platelet therapy. No other immediate procedure-related complications occurred. The median fluoroscopy time was 34 minutes with an interquartile range of 22 to 55 minutes.

DISCUSSION

In this study, we describe a CAS technique that employs aspects of both proximal and distal embolic protection, using existing hardware, with excellent technical success and few complications.

Among various modifications in carotid stent design, closed-cell stents, as opposed to open-cell, have the greatest evidence for reducing periprocedural stroke during CAS. In large-scale randomised controlled trials (RCT), closed-cell stents achieved significantly lower rates of major adverse cardiac and cerebrovascular events (stroke, myocardial infarction, death) than open-cell stents within 30 days of CAS.5,6 In the last five years, novel double-layered micromesh stents have been used to address concerns regarding plaque protrusion and embolic release through large cells. One recent RCT of 104 patients showed that double-layered stents,

| Table 1. Patient demographics and risk factor profile |
|-----------------------------------|----------------|
| Variable                          | Value          |
| Age (y)                           | 69 ± 13        |
| Sex                               |                |
| Male                              | 65 (73.0)      |
| Female                            | 24 (27.0)      |
| Hypertension                      | 62 (69.7)      |
| Hypercholesterolaemia             | 40 (44.9)      |
| Diabetes                          | 24 (27.0)      |
| Smoker/ex-smoker                  | 43 (48.3)      |
| Ischaemic heart disease           | 19 (21.3)      |
| Previous stroke/TIA              | 14 (15.7)      |
| Previous AF                       | 7 (7.9)        |
| New AF                            | 9 (10.1)       |

Values are presented as median:standard deviation or number (%). TIA, transient ischemic attack; AF, atrial fibrillation.

<table>
<thead>
<tr>
<th>Table 2. Lesion characteristics and mechanical thrombectomy data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variable</td>
</tr>
<tr>
<td>Nature of procedure</td>
</tr>
<tr>
<td>Emergency</td>
</tr>
<tr>
<td>Elective</td>
</tr>
<tr>
<td>Pre-procedure anti-platelet therapy</td>
</tr>
<tr>
<td>Emergency</td>
</tr>
<tr>
<td>Elective</td>
</tr>
<tr>
<td>Carotid lesion side</td>
</tr>
<tr>
<td>Right</td>
</tr>
<tr>
<td>Left</td>
</tr>
<tr>
<td>Tandem lesions on DSA</td>
</tr>
<tr>
<td>Location of retrieved tandem lesions</td>
</tr>
<tr>
<td>ICA and terminus</td>
</tr>
<tr>
<td>ICA and MCA</td>
</tr>
<tr>
<td>ICA and ACA</td>
</tr>
</tbody>
</table>

Values are presented as number (%). DSA, digital subtraction angiogram; ICA, internal carotid artery; MCA, middle cerebral artery; ACA, anterior cerebral artery.
compared to single-layered stents, are associated with fewer periprocedural microembolic signals on transcranial Doppler (TCD). However, the overall benefit remains unclear as double-layered stents have also demonstrated a higher risk of acute stent thrombosis.7,8

Embolic protection devices (EPD) are now routinely used during CAS in the context of early CEA versus CAS trials, such as CREST, showing comparable outcomes when EPD was mandated in CAS.9 In 2009, two meta-analyses of trials conducted between 1990 and 2008 also found that EPD were associated with a significant reduction in 30-day stroke or death.10,11 However, a subsequent Cochrane meta-analysis, including data from only major RCTs (EVA-3S, SPACE, ICSS), found that EPDs had no significant effect on 30-day stroke or death (odds ratio 0.95 [95% confidence interval: 0.38–2.41]).2 Thus, the exact benefit of EPDs remains unclear, awaiting further high-quality studies, but is broadly recommended (Level B) by the European Society of Vascular Surgery.12

Based on our experience, the distal EPD usually has a larger profile than the CASPER stent. In addition, extra steps are required to deploy the EPD distal to the carotid stenosis or occlusion compared to CRAFTS which uses a pre-existing step during carotid stenting. Deploying an EPD distal to the stent can be technically challenging and time-consuming, often under time critical operative conditions. Furthermore, the EPD acts as a distal filter that usually does not fully appose the wall, which can lead to embolus bypassing the EPD and causing distal occlusion when combined with a single layer stent (Fig. 2A). In contrast, the stent is designed to fully appose the wall, providing better coverage with more embolic protection (Fig. 2B).

In particular, speculation exists regarding the type of EPD used: proximal (P-EPD) or distal (D-EPD). P-EPD are occlusion balloons placed in the CCA and external carotid artery (ECA), preventing embolisation by causing an arrest or reverse in blood flow while crossing the ICA stenosis and deploying the stent. D-EPD must cross the stenosis to reach the distal ICA, and act to filter antegrade blood and trap emboli dislodged during the procedure. P-EPDs have proven superior to D-EPD when assessed on the basis of surrogate markers of periprocedural stroke, producing significantly fewer microemboli on diffusion weighted MRI and TCD.8,13,14 Nonetheless, no significant difference has been identified in postoperative neurocognitive decline, stroke, or death between P-EPD and D-EPD, and P-EPD are not without their disadvantages. For example, up to one-third of patients may be neurologically intolerant to P-EPD, manifesting symptoms of ipsilateral cerebral hypoperfusion.13,15,16 In addition, P-EPD are larger profile devices than D-EPD and may cause vessel wall injury when deployed in the CCA or ECA. As such, P-EPD are contraindicated for patients with contralateral ICA occlusion and patients with advanced CCA or ECA atherosclerosis.12

There are several theoretical advantages of the CRAFT approach during CAS. CRAFT achieves distal protection with only the CASPER RX stent, avoiding the need to pass and deploy a separate D-EPD across the occlusion. This removes the extra risk of generating emboli as the D-EPD is passed, and avoids the risk of endothelial injury that occurs when the D-EPD is deployed. Having distal protection in addition to arresting antegrade flow is important because balloon deflation causes a rapid return of blood flow, which exerts shear stress on the carotid plaque, potentially leading to microembolisation of particulate debris. By deflating the balloon during stent deployment rather than afterwards, the duration of cerebral circulatory stasis is reduced, which in itself may cause intracerebral thromboembolism and neurological sequelae.16 Although the incidence of distal embolization related to carotid artery stenting in acute ischaemic stroke is not well established, the percentage of cases developing distal embolization in our study (5.3%) was lower than the
recent study published by Jadhav et al. The strength of this study also includes a relatively large cohort size and long study duration. In addition, the procedures were performed by operators with consistent technique. There are several limitations to this technique. For example, some microemboli may still pass intracranially through gaps between the vessel wall and the single-layered flared end of the CASPER RX stent, especially if not deployed sufficiently. Moreover, macroemboli may disintegrate upon being captured by the CASPER stent, potentially leading to microemboli travelling through the stent’s microcells. In addition, there are also limitations of this study including its retrospective nature across two centres, despite homogeneous CAS practice across all operators. Finally, this study focuses on early periprocedural complications and long-term follow-up data will be the subject of future studies.

CONCLUSION

This study presents a method of CAS that can be applied in the treatment of symptomatic carotid artery stenosis in both emergent and elective procedure settings. This technique had a high technical success rate but still had a certain periprocedural complication risk. We aim to further establish the validity of this technique by expanding data collection including long-term outcomes.

Fund
None.

Ethics Statement
This study was approved by the institutional human research ethics committee. As specific patient information such as age or sex is not included, Informed consent for publication is not required.

Conflicts of Interest
The authors have no conflicts to disclose.

Author Contributions
Concept and design: MF, YR, JG, JM, DMB, and HA. Analysis and interpretation: MF, YR, and HA. Data collection: MF, YR, and HA. Writing the article: MF and YR. Critical revision of the article: CDB, HKK, AJ, JM, DMB, and HA. Final approval of the article: HA. Overall responsibility: MF and YR.

ORCID
Michelle Foo: https://orcid.org/0000-0001-8056-1163
Yifan Ren: https://orcid.org/0000-0001-6518-6828
Jay Gajera: https://orcid.org/0000-0003-2395-4520
Christen D Barras: https://orcid.org/0000-0003-1899-1909
Hong Kuan Kok: https://orcid.org/0000-0002-8740-6067
Ashu Jhamb: https://orcid.org/0000-0002-7097-1641
Hussein Abbouchie: https://orcid.org/0000-0002-7913-8584
Julian Maingard: https://orcid.org/0000-0001-8958-2411
Duncan Mark Brooks: https://orcid.org/0000-0001-5034-570X
Hamed Asadi: https://orcid.org/0000-0003-2475-9727

REFERENCES
8. Montorsi P, Caputi L, Galli S, Ravagnani PM, Teruzzi G, Annoni A,
et al. Carotid wallstent versus roadsaver stent and distal versus proximal protection on cerebral microembolization during carotid artery stenting. JACC Cardiovasc Interv 2020;13:403-414